Translating an iTANK-Enhanced CAR-T into the Clinic to Expand Treatment Opportunities for Glioblastoma Patients
2:15 pm - Tuesday 9th February 2027
- Exploring how the iTANK platform is designed to enhance anti-tumour immune responses and address the immunosuppressive tumour microenvironment
- Reviewing the clinical rationale and development strategy underpinning the advancement of ELC-401 into patient evaluation
- Presenting early clinical experience with iTANK-enhanced CAR-T therapy and its potential to address significant unmet need in glioblastoma
